STOCK TITAN

ACADIA Pharmaceuticals (NASDAQ: ACAD) — Vanguard reports 0 shares in amendment

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting that it beneficially owns 0 shares of ACADIA Pharmaceuticals Inc. common stock, representing 0% of the class. The filing explains this reflects an internal realignment and the disaggregated reporting of certain Vanguard subsidiaries under SEC Release No. 34-39538 (January 12, 1998). The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after internal realignment.

The filing records 0 shares and 0% ownership as reported on the amendment; it attributes the change to an internal reorganization and disaggregated reporting by subsidiaries under SEC Release No. 34-39538.

Cash-flow treatment and any trading activity are not stated in the excerpt; subsequent filings by Vanguard subsidiaries may show holdings separately.

Amendment aligns public reporting with SEC guidance on disaggregation.

The amendment cites SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately from The Vanguard Group, Inc. This is a procedural reporting change rather than a transaction.

Stakeholders should reference future 13G/A entries from identified subsidiaries for the substantive ownership picture.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report for ACADIA (ACAD) in this amendment?

Vanguard reports owning 0 shares (0%). The amendment states 0 shares beneficially owned, representing 0% of ACADIA common stock, filed as Amendment No. 9 and signed on 03/26/2026.

Why does the filing say Vanguard shows 0 ownership for ACADIA?

The filing attributes the change to an internal realignment. It cites SEC Release No. 34-39538 and explains certain Vanguard subsidiaries will report holdings separately on a disaggregated basis.

Who signed the Schedule 13G/A amendment for Vanguard?

The amendment is signed by Ashley Grim. Her title is listed as Head of Global Fund Administration and the signature date is 03/26/2026.

Does this amendment show any shares held by Vanguard subsidiaries?

The amendment itself lists 0 shares for The Vanguard Group. It states subsidiaries will report separately; specific subsidiary holdings are not included in this excerpt.

Is this change a sale or purchase of ACADIA stock?

The filing records a reporting reorganization, not a transaction. It explains disaggregated reporting after an internal realignment; no purchase or sale details are provided in the excerpt.